The Lancet · 2013 · 501 citations · 15 references
MedicineOncologyBreast OncologyImmunotherapyMolecular OncologyAdjuvant ImmunotherapyAdjuvant TherapyCancer ImmunotherapyHer2-positive Breast CancerImmunotherapy For Breast CancerMetastatic Breast CancerAdjuvant Her2-directed TherapyHer2 Receptor TargetingHer2-positive Breast Cancer ImmunotherapyHer2-positive Breast Cancer TherapyHuman Epidermal Growth Factor Receptor 2-Targeted Therapy
15
The Statistical Analysis of Failure Time Data.
Murray Aitkin, John D. Kalbfleisch, Ross L. Prentice · Biometrics · 1981 · 10K citations
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, Edith A. Perez, John Bryant et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text
Medicine, Oncology, Pharmacology +16
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis J. Slamon, W. Eiermann, Nicholas J. Robert et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +17